WO1982001875A1 - Inhibitors of transpeptidase - Google Patents

Inhibitors of transpeptidase Download PDF

Info

Publication number
WO1982001875A1
WO1982001875A1 PCT/US1981/000109 US8100109W WO8201875A1 WO 1982001875 A1 WO1982001875 A1 WO 1982001875A1 US 8100109 W US8100109 W US 8100109W WO 8201875 A1 WO8201875 A1 WO 8201875A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
formula
loweralkyl
hydrogen
compounds
Prior art date
Application number
PCT/US1981/000109
Other languages
French (fr)
Inventor
Lab Abbott
Daniel T Chu
Original Assignee
Lab Abbott
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US06/212,006 external-priority patent/US4347355A/en
Application filed by Lab Abbott filed Critical Lab Abbott
Priority to AU73225/81A priority Critical patent/AU7322581A/en
Publication of WO1982001875A1 publication Critical patent/WO1982001875A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D477/00Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring
    • C07D477/10Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
    • C07D477/24Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hetero atoms or carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 6

Definitions

  • the present invention is thus concerned with new antibacterials, compounds of the formula:
  • R represents H or an acyl moiety known from the penicillin or cephalosporin art
  • R' is hydrogen, loweralkoxy, 1oweraikoxyalkyl, loweralkyl, phenylmercapto or loweralkylmercapto
  • R" is loweralkyl
  • the broken line represents an optional double bond
  • Acyl groups found particularly useful are phenacetyl, phenoxyacetyl, cyanoacetyl, thenylacetyl,
  • Y is 0 or NOR" , or a mercaptoacetyl of the formula R°SCH 2 CO- wherein R° is phenyl, 4-pyridyl, 2-chloro-2-butenyl, allyl or n-butyl.
  • Example 1 To a cold solution of 13.1 g of dibenzyl phthalimidomalonate in 300 ml dry dimethoxyethane (DME) is slowly added 1.47 g of a 50% sodium hydride-in-oil suspension. After stirring at room temperature for 30 min., 16.2 g 1-chloro-1-phenylthio-2,2-dimethyl-3-ethylenedioxy- propane is added and the mixture is refluxed 30 hrs. and then filtered. The filtrate is condensed under reduced pressure to a volume. of 50 ml. This concentrate is added to 250 ml of ice-cold water and extracted with three 200 ml portions of CH 2 Cl 2 . The organic phase is dried over
  • Example 2 a) To an ice-cold solution of 3 g of compound VI of Example 1 and 1.68 g NaHCO 3 in 50 ml of water is added
  • R' is phenylthio , R" is methyl and the 5-membered ring is saturated. Further following Example 2 produces moderate yields of I wherein R and R" have the above meaning, R' is H and the 2-3 positions are connected by a double bond.
  • Example 4 In the described fashion of Example 2, using
  • Example 1(d) is mixed with 1.68 g NaHCO 3 in 50 ml of water. This mixture is stirred for 3 hrs. with 4 g of the succinimide ester of benzoylglycyl-phenylglycine in 50 ml of dimethoxyethane. The solvent is stripped to about 10 ml under reduced pressure and water is added followed by extraction with CH 2 Cl 2 .
  • the aqueous phase is acidified with HCl to pH 3, forming a precipitate identified as 6- (N-benzoylglycylphenylglycylamino) -1 , 1-dimethyl-2- ⁇ henyl- thio-4-azabicyclo[2,0,3]heptan-5-one-3-carboxylic acid.
  • Example 7 By replacing the succinimide used in Example 6 with the succinimide of the acid of structure
  • Example 8(c) is obtained in good yield, carrying a methoxy group in the 2-position in place of the phenylmercapto group.
  • Example 10 To a solution of 4.5 g. of the compound of Example 9(a) in 30 ml CH 2 Cl 2 is added a mixutre of 0.75 ml ethanethiol and 1 ml triethylamine. Refluxing for 15 hrs. and evaporation under reduced pressure produces the ethylmercapto- ⁇ 2 -analog of the compound of Example 8(c) in almost quantitative yield
  • Example 12 To a solution of 5.6 g of the compound of Example 8(b) in 100 ml dry THF at 0°C is added 3.33 ml of a 3-molar solution of methylmagnesium chloride. After stirring for 1 hr., 2.1 g sodium periodate is added and the mixture is refluxed for 15 hrs. This is followed by the usual workup using CH 2 Cl 2 and a carbon column to produce an oil identified as I wherein R is phenoxyacetyl, R' and R" are methyl, the 5-membered ring is unsaturated and the carboxy group is esterified with benzyl.
  • aminothiazylacetyl 5 aminoglutaroyl
  • the saturated and unsaturated 2-substituted or unsubstituted compounds are active against pseudomonas .
  • the 2-unsubstituted compounds are best obtained from the 2-phenylmercapto- ⁇ 2 -compounds in yields of 65-80% and ordinarily are more active, i.e., they require a lower dosage than the 2-phenylmercapto compounds.
  • In vitro activity of the latter compounds are generally found at 100-500 ppm; the unsaturated analogs are active at 1-250 ppm against numerous infectuous, gram-positive bacteria.
  • the preferred method for this reaction consists in treating compound IV in an inert organic solvent, for instance methy1ene chloride or DME, with an azidoacetyl halide in the presence of an acid acceptor at a temperature below room temperature , preferably between -25 ° C and + 10 ° C.
  • Azidoacetyl chloride is an excellent agent for this reaction, although corresponding other acylating agents derived from azidoacetic acid are equally useful.
  • Acid acceptors include trialkylamines, such as trimethylamine or triethylamine.
  • the obtained azidoester V is then easily converted to the desired bicyclic, primary amine VI, by hydrogenating V.
  • a preferred method for this step is catalytic hydrogenation, using a noble metal catalyst, although Raney nickel can also be used.
  • noble metals palladium is preferred, although platinum or ruthenium can be used as well.

Abstract

New ss-lactams of the general structure: (FORMULA) wherein R represents H or an acyl moiety known from the penicillin or cephalosporin art, R' is hydrogen, lower alkoxy, lower alkoxyalkyl, lower alkyl, phenylthio or lower alkylmercapto, R' is lower alkyl, the broken line represents an optional double bond, and acyloxymethyl esters thereof. All compounds are effective antibacterials.

Description

INHIBITORS OF TRANSPEPTIDASE
This application is a continuation-in-part of U.S. Serial Number 123,142, filed February 21, 1980.
Detailed Description of the Invention
Many cephalosporin and penicillin derivatives have been synthesized in the past 30 years and many of them have found their way into the arsenal of anti-biotic drugs with a broad spectrum of antibacterial activity. However, the bacteria combatted in this fashion have learned to adapt to the attacks by these antibiotics and have formed strains resistant to the antibiotics. It is therefore of great importance to find new antibiotics to which resistance has not yet developed in infectious bacteria. Basic changes in the structure of known antibiotics are particularly well suited to overcome the bacterial resistance to known therapeutics.
The present invention is thus concerned with new antibacterials, compounds of the formula:
Figure imgf000003_0001
wherein R represents H or an acyl moiety known from the penicillin or cephalosporin art, R' is hydrogen, loweralkoxy, 1oweraikoxyalkyl, loweralkyl, phenylmercapto or loweralkylmercapto, R" is loweralkyl, the broken line represents an optional double bond, and acyloxymethyl esters thereof. Acyl groups found particularly useful are phenacetyl, phenoxyacetyl, cyanoacetyl, thenylacetyl,
D-hydroxyphenylmalonoyl,α-aminophenacetyl, α-sulfophenacetyl N-benzoylglycylphenylglycyl a moiety of the formula
,
Figure imgf000003_0002
Figure imgf000003_0003
Figure imgf000004_0002
wherein Y is 0 or NOR" ,
Figure imgf000004_0001
or a mercaptoacetyl of the formula R°SCH2CO- wherein R° is phenyl, 4-pyridyl, 2-chloro-2-butenyl, allyl or n-butyl.
The compounds wherein R ≠ H and R' is phenylmercapto or alkoxy and the 2,3-positions are connected by a single bond are less active than the corresponding unsaturated compounds. All the compounds, however, show activity against numerous infectious and other bacteria, as can easily be demonstrated on cultures of pseudomonas strains at concentrations of 1 to 500 ppm. The new compounds will completely prevent any further growth of Staph. aureus and in the higher concentration ranges mentioned will produce a bacteriocidal effect.
The above compounds are prepared by the following scheme:
Figure imgf000004_0003
Figure imgf000004_0004
Figure imgf000004_0005
Figure imgf000004_0006
R = varies R = varies
I ={ R' = PhS, saturated→ R' = H,Δ2 R" - loweralkyl R" - loweralkyl
In order to illustrate the manufacture of the compounds of this invention, reference is made to the following examples which however, are not to be interpreted as limitations of the scope of this invention. In all instances, microanalyses are used to verify the identity of the expectec compounds.
Example 1 a) To a cold solution of 13.1 g of dibenzyl phthalimidomalonate in 300 ml dry dimethoxyethane (DME) is slowly added 1.47 g of a 50% sodium hydride-in-oil suspension. After stirring at room temperature for 30 min., 16.2 g 1-chloro-1-phenylthio-2,2-dimethyl-3-ethylenedioxy- propane is added and the mixture is refluxed 30 hrs. and then filtered. The filtrate is condensed under reduced pressure to a volume. of 50 ml. This concentrate is added to 250 ml of ice-cold water and extracted with three 200 ml portions of CH2Cl2. The organic phase is dried over
MgSO4, evaporated, and the obtained oil is chromatographed over florisil to produce III (R" = CH3 ) in good yield. b) A solution of 6.6 g of the dibenzylester acetal III in 30 ml THF is refluxed with 500 mg hydrazine hydrate for 90 min. The resulting mixture is poured into ice-cold water and extracted with CH2Cl2. The original phase is purified over an alumina column to give the substituted malonic ester III wherein the phthalimino group is replaced by the amino group and R" is methyl. A solution of 5.3 g of this aminoester in 30 ml THF is then refluxed for 2 hrs. with 30 ml aqueous 0.5 N HCl. After evaporating the mixture under reduced pressure and placing the residue in 60 ml CH2Cl2; 1.5 ml of triethylamine and 50 g anhydrous MgSO4 are added and the mixture is allowed to stand overnight. Upon subsequent filtration, washing with cold water and evaporation, 4.5 g of the cyclic d iester IV is obtained as an oil in excellent yield. c) A solution of 9-5 g IV in 200 ml dry CH2Cl2 is cooled to -10ºC in an ice-methanol bath before 2.8 ml of triethylamine is added, followed by a dropwise addition of a solution of 2.4 g azidoacetyl chloride in 35 ml CH2Cl2 over a period of 15 min. The mixture is then stirred another 15 min. and washed with water. Work-up in the fasipn of (a) above produces a moderately high yield of V (R"=Me). d) To a solution of 5.6 g of the azidoester V in 100 ml glacial acetic acid, 500 mg 10% Pd-on-carbon is added and the mixture is hydrogenated at room temperature for 1 hr., at which time the mixture is filtered and the filtrate is heated for 3 hrs. at 60°C. Solvent removal produces a moderately high yield of 6-amino-1,1-dimethyl-2-phenylthio-4-azabicyclo[2,0,3]heptan-5-one-3-carboxylic acid (VI;R"=Me).
Example 2 a) To an ice-cold solution of 3 g of compound VI of Example 1 and 1.68 g NaHCO3 in 50 ml of water is added
2.5 g o N-(ρhenoxymethylcarbonyloxy)-succinimide in 50 ml dimethoxye thane. The mixture is stirred for 3 hrs. and the volume is then reduced to about 10 ml under reduced pressure. Water is added and the mixture is extracted with CH2Cl2. The aqueous phase is acidified with HCl to pH 6 which produces 1.1-dimethyl-6-phenoxy-acetylamino-2-phenylthio-4-azabicyclo[2,0,3]heptan-5-one-3-carboxylic acid in excellent yield. b) A solution of 4.4 g of this material in 100 ml CH2Cl2 is stirred with 1.7 g m-chloroperbenzoic acid for
16 hrs., before adding 2.2 g of chlorotrimethylsilane and 3 g of triethylamine and refluxing this mixture for 5 hrs. The reaction product is diluted with water and extracted with ether. The organic phase is dried over MgSO4 and evaporated to produce a solid residue. Repeated precipitation of this crude material from ether/pentane produces pure 1,1-dimethyl-6-phenoxyacetyiamino-4-azabicyclo[2,0,3]-2-hepten-5-one-3-carboxylic acid in a moderate yield. Example 3 By following the preceding Example but substituting the above succinimide with 4.1 g of 1-ρhenyl-1-(4-ethyl- 2 3-dioxo-1-piperazinyl) carboxamidoacetoxy succinimide, one obtains I wherein R is
Figure imgf000007_0001
R' is phenylthio , R" is methyl and the 5-membered ring is saturated. Further following Example 2 produces moderate yields of I wherein R and R" have the above meaning, R' is H and the 2-3 positions are connected by a double bond.
Example 4 In the described fashion of Example 2, using
5.9 g of
Figure imgf000007_0002
in place of the mentioned succinimide, the correspondingly N-substituted derivatives I are obtained: in the first step, R' is Ph-S- and the ring is saturated; in the second step, R' becomes H while introducing ring unsaturation (R and R" being as described) with R" being methyl in both instances.
Example 5 1.36 of sulfophenylacetyl chloride in 10 ml ether is dropwise added to a stirred solution of 1.5 g of VI from Example 1 in 50 ml of water containing 200 mg NaOH and 850 mg NaHCO3 at 0-5°C. After 30 min., the organic layer is removed and the pH of the aqueous phase is adjusted to 6, followed by lyophylization of the acidified solution. Crystallization from water-pyridine-acetone produces the N-sulfophenylacetyl derivatives of VI (R° and R" as before, no double bond) as colorless needles. Proceeding in the fashion shown in Example 2, compound I is obtained (R=NaO3S- CHPh-CO-, R'=H, R"=Me with double bond 2-3) in moderate yield.
Example 6 An ice-cold solution of 2.8 g of the compound of
Example 1(d) is mixed with 1.68 g NaHCO3 in 50 ml of water. This mixture is stirred for 3 hrs. with 4 g of the succinimide ester of benzoylglycyl-phenylglycine in 50 ml of dimethoxyethane. The solvent is stripped to about 10 ml under reduced pressure and water is added followed by extraction with CH2Cl2. The aqueous phase is acidified with HCl to pH 3, forming a precipitate identified as 6- (N-benzoylglycylphenylglycylamino) -1 , 1-dimethyl-2-ρhenyl- thio-4-azabicyclo[2,0,3]heptan-5-one-3-carboxylic acid. By treating this material as in Example 2(b), the compound of structure I is obtained wherein R is N-benzoylglycylphenylglycyl, R'=H, R"=Me and the 5-membered ring is unsaturated in good yield.
Example 7 By replacing the succinimide used in Example 6 with the succinimide of the acid of structure
wherein the amino group is protected by the triphenylmethyl group, one obtains initially the compound of I (R is the acyl group of VII, R' is phenylmercapto and R" is Me) and after treatment with m-chlorobenzoic acid, the 2-substituent is removed while a double bond is introduced simultaneously into the 5-membered ring.
Example 8 a) To 4.4 g of the product of Example 2(a) in 40 ml of DMF is added 480 mg sodium hydride as a 50% oil suspension and after 15 min. of stirring, 1.7 g benzylbromide together with a catalytic amount of tetrabutylammonium iodide are added. The mixture is stirred for 4 hrs. and poured into water. Extraction of the aqueous mixture with CH2Cl2, drying the extract with MgSO4 and evaporation produces an oil which is purified on neutral almina; it is identified as the benzyl ester of the compound of Example 2(a). b) Treating 5.3 g of this compound in 20 ml carbon tetrachloride with 1.33 g of N-chlorosuccinimide under a sun lamp and with stirring for 5 hrs., filtering the mixture and evaporation produces the 2-chloro-2-phenylmercapto analog of the described benzyl ester in excellent yield calculated from the compound of Example 2(a). c) A solution of 5.6 g of this compound in 50 ml
CH2Cl2 is heated for 3 hrs. with 1.1 g of triethylamine. The mixture is then washed with cold water. The organic layer is dried and evaporated to produce a nearly theoretical amount of the analog of the compound of (a) above but containing a double bond between the 2-3 positions. d) A solution of 1.33 g anhydrous AICI3 in nitromethane is added to a solution of 5.3 g of the compound of c) above in 2 g anisole and 20 ml CH2Cl2 under ice cooling. After stirring at room temperature fo r 5 hrs., the mixture is diluted with ethyl acetate, washed with dilute HCl and extracted with 5% aqueous NaHCO3. The aqueous extract is acidified with HCl and then extracted with ethyl acetate. The original layer is washed with water, dried over MgSO4 and evaporated to give a solid residue. After recrystallization from acetone/pentane, the pure unsaturated compound I (R=phenoxyacetyl, R'=phenylmercapto, R"= Me) is obtained in good yield. Example 9 a) When 5.3 g. of the compound of example 8(c) in 50 ml of methanol is stirred with 2.1 g sodium metaperiodate at 0ºC for 5 hrs. followed by refluxing for 15 hrs., evaporation and the CH2Cl2 extraction procedure of Example 1(a), the analog of Example 8(c) is obtained in good yield, carrying a methoxy group in the 2-position in place of the phenylmercapto group. b) Removal of the ester group is carried out as in Example 8(d) to produce a good yield of the 2-3 unsaturated I (R=phenoxyacetyl, R'=methoxy, R"=Me).
Example 10 To a solution of 4.5 g. of the compound of Example 9(a) in 30 ml CH2Cl 2 is added a mixutre of 0.75 ml ethanethiol and 1 ml triethylamine. Refluxing for 15 hrs. and evaporation under reduced pressure produces the ethylmercapto-Δ2-analog of the compound of Example 8(c) in almost quantitative yield
Upon ester group removal as in Example 8(d), unsaturated compound I (R=phenoxyacetyl, R'=EtS, R"=Me) is obtained in very good yield.
Example 11
By following the procedure of Example 9(a) and 9(b) with 5.6 g of the compound of Example 8(c) but using 20 ml of methoxyethanol in place of methanol, compound I (Δ2, R=ρhenoxyacetyl, R'=MeOCH2CH2O, R"=Me) is obtained in good yield.
Example 12 To a solution of 5.6 g of the compound of Example 8(b) in 100 ml dry THF at 0°C is added 3.33 ml of a 3-molar solution of methylmagnesium chloride. After stirring for 1 hr., 2.1 g sodium periodate is added and the mixture is refluxed for 15 hrs. This is followed by the usual workup using CH2Cl2 and a carbon column to produce an oil identified as I wherein R is phenoxyacetyl, R' and R" are methyl, the 5-membered ring is unsaturated and the carboxy group is esterified with benzyl.
Removal of the benzyl ester group in the fashion of Example 8(d) produces the unsaturated compound I (R=phenoxyacetyl, R'=R"=Me).
Example 13
To 3.2 g of the product in Example 2(b) in 25 ml DME is added 480 mg sodium hydride as a 50% oil suspension and, after 5 minutes of stirring, 1.5 g chloromethyl pivalate is added. After 2 1/2 hrs. the mixture is evaporated and the residue is redissolved in methylene chloride, washed with water, dried and evaporated. It is purified through column chromatography on alumina, yielding the pivaloxymethyl ester of 2(b) (R = PhOCH2CO; R' = H; R" = CH3).
Example 14 In the described procedure as in Example 13, using α-pivaloxy ethyl chloride instead of chloromethyl pivalate, α-pivaloxy ethyl ester of 2(b) (R = PHOCH2CO, R' = H, R" = CH3) is obtained.
By following Example 13 but substituting the product of Example 2(b) by the compounds of Examples 3-12, the corresponding pivaloxymethyl esters of the shown free acids are obtained.
In similar fashion, the use of the succinimino esters or acid chlorides of various other acyl groups frequently used in the cephalosporin or penicillin series, leads to the saturated compounds of structure I wherein R' is phenylthio, alkoxy, alkylthio, aikoxyalkyl and R" is any loweralkyl, and ultimately to the 2-3 unsaturated (or Δ2) compounds and their acyloxymethyl esters with R'=H, alkyl, phenylmercapto, alkoxy, alkyimercapto or alkoxyalkoxy, showing the following acyl groups in the 6-position:
R = phenacetyl = phenoxyacetyl = cyanoacetyl = thenylacetyl
= p-hydroxyphenylmalonoyl = α - aminophenacetyl
= α - sulfophenylacetyl
= aminothiazylacetyl = 5 aminoglutaroyl
,
Figure imgf000012_0001
Figure imgf000012_0002
or
Figure imgf000012_0003
Figure imgf000012_0004
In all cases, the saturated and unsaturated 2-substituted or unsubstituted compounds , are active against pseudomonas .The 2-unsubstituted compounds are best obtained from the 2-phenylmercapto-Δ2-compounds in yields of 65-80% and ordinarily are more active, i.e., they require a lower dosage than the 2-phenylmercapto compounds. In vitro activity of the latter compounds are generally found at 100-500 ppm; the unsaturated analogs are active at 1-250 ppm against numerous infectuous, gram-positive bacteria.
One of the most important steps of the reaction sequence leading to the new compounds of this invention is the ring closure step for the azetidine ring. The preferred method for this reaction consists in treating compound IV in an inert organic solvent, for instance methy1ene chloride or DME, with an azidoacetyl halide in the presence of an acid acceptor at a temperature below room temperature , preferably between -25 ° C and + 10 ° C. Azidoacetyl chloride is an excellent agent for this reaction, although corresponding other acylating agents derived from azidoacetic acid are equally useful. Acid acceptors include trialkylamines, such as trimethylamine or triethylamine. The obtained azidoester V is then easily converted to the desired bicyclic, primary amine VI, by hydrogenating V. A preferred method for this step is catalytic hydrogenation, using a noble metal catalyst, although Raney nickel can also be used. Among noble metals, palladium is preferred, although platinum or ruthenium can be used as well.

Claims

WE CLAIM :
1 . A compound of the formula
Figure imgf000014_0001
wherein R is hydrogen or an acyl group known from the penicillin and cephalosporin art to impart beneficial antibacterial properties to the molecule, R' is hydrogen, loweralkyl, loweralkoxyalkyl, loweralkoxy, loweralkylmercapto or phenylmercapto, each R" is loweralkyl, and the broken line represents an optional double bond, and acyloxymethyl esters thereof.
2. A compound in accordance to Claim 1 wherein said acyl group is phenacetyl, phenoxyacetyl, cyanoacetyl, thenylacetyl, o-hydroxyphenylmalonoyl, α-aminophenacetyl, α-sulfophenacetyl, N-benzoylglycylphenylglycyl, a moiety of the formula
.
Figure imgf000014_0002
Figure imgf000014_0003
Figure imgf000014_0004
,
wherein ϊ is Q or NOR" ,
Figure imgf000014_0005
or a mercaptoacetyl of the formula R°SCH2CO-wherein R° is phenyl, 4-pyridyl, 2-chloro-2-butenyl, allyl or n-butyl.
3. The unsaturated compound of Claim 1 wherein is H.
4. The compound of Claim 3 wherein each R" is methyl and R is H.
5. The compound of Claim 2 wherein R is H.
6. The process of preparing a compound of the formula
Figure imgf000015_0002
wherein R" is H or loweralkyl, consisting essentially in reacting a compound of the formula
Figure imgf000015_0001
in the presence of an inert organic solvent and an acid acceptor at a temperature of between -25°C and +10°C with at least one molar equivalent of an azidoacetyl halide and subsequently treating the formed azidoester with hydrogen gas in the presence of a hydrogenation catalyst.
7. The process of Claim 6 wherein said organic solvent is methylene chloride.
8. The process of Claim 6 wherein said halide is azidoacetyl chloride.
9. The process of Claim 6 wherein said catalyst is palladium.
PCT/US1981/000109 1980-12-01 1981-01-19 Inhibitors of transpeptidase WO1982001875A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU73225/81A AU7322581A (en) 1980-12-01 1981-01-19 Inhibitors of transpeptidase

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/212,006 US4347355A (en) 1980-02-21 1980-12-01 Inhibitors of transpeptidase
US212006801201 1980-12-01

Publications (1)

Publication Number Publication Date
WO1982001875A1 true WO1982001875A1 (en) 1982-06-10

Family

ID=22789166

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1981/000109 WO1982001875A1 (en) 1980-12-01 1981-01-19 Inhibitors of transpeptidase

Country Status (1)

Country Link
WO (1) WO1982001875A1 (en)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4013648A (en) * 1975-07-23 1977-03-22 Bristol-Myers Company Δ2,3 -0-2-Isocephem-4-carboxylic acid and derivatives as antibacterial agents
US4218463A (en) * 1977-12-28 1980-08-19 Merck & Co., Inc. 3-Substituted thio-6-amido-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
US4218459A (en) * 1977-12-28 1980-08-19 Merck & Co., Inc. 6-Amido-1-carba-2-penem-3-carboxylic acid
US4224336A (en) * 1979-04-17 1980-09-23 Merck & Co., Inc. 3-(2-Aminoethylthio)-6-amido-7-oxo-1-azabicyclo[3.2.0]-hept-2-ene-2-carboxylic acid
US4262009A (en) * 1979-12-03 1981-04-14 Merck & Co., Inc. 6- And 1,1-disubstituted-1-carbadethiapen-2-em-3-carboxylic acid
US4277482A (en) * 1979-10-15 1981-07-07 Merck & Co., Inc. 3-Substituted thio-6-amido-7-oxo-1-azabicyclo[3.2.0]-hept-2-ene-2-carboxylic acid s-oxides

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4013648A (en) * 1975-07-23 1977-03-22 Bristol-Myers Company Δ2,3 -0-2-Isocephem-4-carboxylic acid and derivatives as antibacterial agents
US4218463A (en) * 1977-12-28 1980-08-19 Merck & Co., Inc. 3-Substituted thio-6-amido-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
US4218459A (en) * 1977-12-28 1980-08-19 Merck & Co., Inc. 6-Amido-1-carba-2-penem-3-carboxylic acid
US4224336A (en) * 1979-04-17 1980-09-23 Merck & Co., Inc. 3-(2-Aminoethylthio)-6-amido-7-oxo-1-azabicyclo[3.2.0]-hept-2-ene-2-carboxylic acid
US4277482A (en) * 1979-10-15 1981-07-07 Merck & Co., Inc. 3-Substituted thio-6-amido-7-oxo-1-azabicyclo[3.2.0]-hept-2-ene-2-carboxylic acid s-oxides
US4262009A (en) * 1979-12-03 1981-04-14 Merck & Co., Inc. 6- And 1,1-disubstituted-1-carbadethiapen-2-em-3-carboxylic acid

Similar Documents

Publication Publication Date Title
CA1080713A (en) Process for the manufacture of 3-substituted-hydroxy-crotonic and isocrotonic acid derivatives
US4347355A (en) Inhibitors of transpeptidase
JPH0557980B2 (en)
US4182711A (en) Antibacterial agents of the β-lactam type
US4155912A (en) 2-Methylpenem-3-carboxylic acid antibiotics
EP0928787B1 (en) Process for the preparation of 3-amino-pyrrolidine derivatives
KR900001170B1 (en) A preparation process for 4-acetoxy-3-hydroxyl ethyl-azetizin-2-one derivatives
WO1982001875A1 (en) Inhibitors of transpeptidase
HU192819B (en) Process for preparing antibacterial penemic derivatives
US4397784A (en) Inhibitors of transpeptidase
EP0001715A2 (en) Azetidinone antibiotics and their pharmaceutical formulations and use
JPS5936914B2 (en) Cephalosporin analogs
NO169716B (en) ANALOGY PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE BICYCLIC BETA-LACTAM CARBOXYL ACIDS
US5332731A (en) Cephalosporin derivatives
US4810788A (en) Azetidinone disulfide derivatives and a process for preparing the same
KR910005230B1 (en) Process for producing azetidinones
IE45593B1 (en) 4-(3-amino-3-carboxypropoxy)glyxylic acid derivatives and processes for their preparation
KR940009532B1 (en) Process for production of pyran derivatives
SE460197B (en) NEW CARBAPENE MEMBER DERIVATIVES AND PROCEDURES FOR PREPARING THEREOF
JP3684339B2 (en) Method for producing carbapenem compounds
US4169833A (en) Novel phosphorane intermediates for use in preparing penem antibiotics
US4192801A (en) Novel phosphorane intermediates for use in preparing penem antibiotics
JP2604794B2 (en) Method for producing 4-acetoxy-3-hydroxyethylazetidin-2-one
GB2079744A (en) 6-Alkyl-2-functionalized penems
AU677986B2 (en) N-substituted 2-azetidinones

Legal Events

Date Code Title Description
AK Designated states

Designated state(s): AU JP

AL Designated countries for regional patents

Designated state(s): AT CH DE FR GB NL SE

WA Withdrawal of international application